19.8 C
London
Saturday, July 20, 2024

    Emerging Growth Conference 74 - August 21 & 22 - Register now

    Emerging Growth Conference 73

    July 17 & 18, 2024

    Agenda Wednesday July 17, 2024

    BlockchainK2 Corp. (OTCQB: BIDCF) (TSXV: BITK) is working to build a bridge from the blockchain sector to traditional capital markets and to represent one of the few pure play ways for stock market equity investors to get exposure to the cryptocurrency market via investment in mining and infrastructure, and proprietary SaaS blockchain solutions with leading industry partners.

    Keynote speaker: Scott Brooks, CEO of RealBlocks

    iQSTEL Inc. (OTCQX: IQST) is a multinational company preparing for a Nasdaq up-listing with an FY2023 $144 million revenue, and with a $290 Million Dollar Revenue forecast and a Positive Operating Income of 7 digits forecast for FY-2024

    Keynote speaker: Leandro Jose Iglesias, Co-Founder, Chairman, President & CEO

    ASP Isotopes Inc. (NASDAQ: ASPI) is a pre-commercial stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries.

    Keynote speaker: Paul Elliot Mann, CEO

    Cyios Corp. (OTC Pink: CYIO) is a publicly traded holding company focused on innovative tech, blockchain, Web3/NFT and carbon offsets and owns numerous subsidiary businesses including CarbonCred, Helio Lending, Randombly, and Immortals Group.

    Keynote speaker: John O’Shea, Chairman

    22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. 

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    Peninsula Energy Limited (OTCQB: PENMF) (ASX: PEN) is a uranium company providing US production and direct market exposure. Its’ 100% owned Lance Projects in Wyoming is due to re-commence production in December 2024 following a central processing plant capacity expansion construction project.

    Keynote speaker: Wayne W. Heili, MD, CEO & Director

    US Energy Corporation (NASDAQ: USEG) is a growth company focused on consolidating high-quality assets in the United States with the potential to optimize production and generate free cash flow through low-risk development while maintaining an attractive shareholder returns program.

    Keynote speaker: Ryan Smith, CEO

    Big Screen Entertainment Group (OTC Pink: BSEG) launched in 2005, is a well-established distribution and production company based in Beverly Hills built on a love for storytelling and has grown to specialize in production, post-production, and distribution in the US and Internationally.

    Keynote speakers: Monroe Mann, VP of Development of Big Film Fund

    Intellabridge Technology Corporation (CSE: KASH) (OTCQB: KASHF) (FSE: KASH) is a fintech company in the business of impact finance whose product, Karma, has a mission to make every transaction have a positive impact on the world through cashback solutions and automated customizable donations to charitable organizations.

    Keynote speaker: John Eagleton, CEO

    LogicMark, Inc. (NASDAQ: LGMK) provides personal emergency response systems (PERS), health communications devices, personal safety apps, services, and technologies to create a Connected Care Platform.

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

    Targa Exploration Corp. (CSE: TEX) (OTCQB: TRGEF) is a Canadian exploration company engaged in the acquisition, exploration, and development of lithium and gold mineral properties with headquarters in Vancouver, British Columbia.

    Keynote speaker: Cameron Tymstra, President & CEO

    ReGen III Corp. (OTCQB: ISRJF) (TSXV: GIII) is a clean technology company commercializing its patented ReGen™ technology to upcycle UMO into high-value Group III base oils. 

    Keynote speaker: Mark Redcliffe, President

    Agenda Thursday July 18, 2024

    Immuron Limited (ASX: IMC) (NASDAQ: IMRN), is a biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

    Keynote speaker: Steve Lydeamore, CEO

    CytoMed Therapeutics, Ltd. (NASDAQ: GDTC) is a biopharmaceutical company that focuses on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. 

    Keynote speaker: Peter Choo, Chairman

    Ethema Health Corporation (OTCQB: GRST), together with its subsidiaries, operates in the behavioral healthcare space specifically in the treatment of substance use disorders.

    Keynote speaker: Shawn E. Leon – CEO

    NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases.

    Keynote speaker: Hyung Heon Kim, Chief Executive Officer and President

    Nascent Biotech, Inc. (OTCQB: NBIO) is a phase 2 clinical-stage biotech company pioneering the development of human monoclonal antibodies to be used in the treatment of various cancers, helping people worldwide.

    Keynote speaker: Sean Carrick, President / CEO

    GeoVax Labs, Inc. (NASDAQ: GOVX) is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases.

    Keynote speaker: David Dodd, Chairman, President / CEO

    Elutia, Inc. (NASDAQ: ELUT) develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. 

    Keynote speaker: Dr. Randy Mills, President & CEO

    CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biotechnology company focused on developing treatments for degenerative diseases of the brain.

    Keynote speaker: Bill Elder, CFO & General Counsel

    Bioxytran, Inc. (OTCQB: BIXT) is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. 

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    AseptiScope, Inc., driven to bring forward novel solutions that ensure “Infection Protection for Clinician & Patient.”, is a privately funded San Diego based company founded in 2016 and led by clinical innovation experts, leading medical researchers, and practicing physicians.

    Keynote speaker: Scott W Mader – Founder & CEO

    NurExone Biologic Inc. (OTCQB: NRXBF) (TSXV: NRX) is a Pharmaceutical Company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. 

    Keynote speaker: Dr. Lior Shaltiel – CEO

    Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. 

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    Regen BioPharma Inc. (OTC Pink: RGBP) is a biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    Ascend Wellness Holdings Inc. (OTCQX: AAWH) owns and operates state-of-the-art cultivation facilities, growing award-winning strains and producing a curated selection of products for retail and wholesale customers

    Keynote speaker: John Hartmann, CEO

    Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is developing tecarfarin for unmet needs in anticoagulation therapy.

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. 

    Keynote speaker: Joshua Disbrow, Chairman, CEO

    Clene Inc., (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. 

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Brown, CFO

    The Emerging Growth Conference focus and coverage includes a wide range of growth sectors and timely market themes, including, augmented reality, artificial intelligence, scientific, medical instruments and therapeutics, biotechnologies, cannabis, food & beverage, energy and more.

    Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally.

    The presentations to be delivered by the presenting companies (including any handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with the offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.